Stocktoria
SERA PROGNOSTICS, INC. SERA
Nasdaq · stock · Services-Medical Laboratories · website · IPO 2021-07-15
SERA PROGNOSTICS, INC. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $81,000 | $77,000 | $306,000 | $268,000 | $82,000 | $25,000 |
| R&D expense | $13.2M | $14.7M | $15.2M | $14.2M | $11.0M | $7.8M |
| Operating income | -$36.5M | -$36.6M | -$39.8M | -$45.7M | -$35.4M | -$18.0M |
| Interest expense | $9,000 | $28,000 | $55,000 | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$31.9M | -$32.9M | -$36.2M | -$44.2M | -$35.0M | -$19.8M |
| EPS (diluted) | $-0.67 | $-0.99 | $-1.16 | $-1.43 | $-2.33 | $-12.76 |
| Operating cash flow | -$25.6M | -$14.2M | -$27.2M | -$34.6M | -$31.6M | -$16.9M |
| Free cash flow | -$26.3M | -$14.2M | -$27.3M | -$35.4M | -$32.9M | -$17.0M |
| Cash & equivalents | $3.9M | $4.0M | $3.9M | $29.9M | $58.9M | $13.5M |
| Total assets | $101.9M | $72.6M | $95.4M | $116.3M | $147.0M | $14.8M |
| Total liabilities | $26.5M | $24.8M | $25.3M | $17.4M | $8.5M | $12.3M |
| Shareholders' equity | $75.4M | $47.8M | $70.2M | $98.9M | $138.6M | -$125.6M |
Growth · year-over-year · Revenue CAGR 26.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +5.2% | -74.8% | +14.2% | +226.8% | +228.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.